Vaccine Manufacturing with SUMO
Revolutionary protein expression technology for next-generation vaccines
Need Help?
- Vaccine Manufacturing as SUMO Fusions
Success of mRNA vaccines has taken the world by storm. However, many vaccines, especially animal vaccines, have not adopted mRNA approaches. SUMO mediated dramatic enhancement of protein production in E.coli provides a rapid and inexpensive approach to develop protein vaccines, especially for the veterinary markets.
- The SUMO Tag
- Understanding SUMO
It is important to understand why the SUMO system has proven to be the best among all other fusion systems (consult LifeSensors’ SUMO Search Engine). The chaperoning properties of SUMO promote correct folding and protect the vaccine from degradation. These factors contribute to dramatically enhance protein production and improve quality of the vaccine.
E.coli provides an attractive platform to express animal vaccines for its low cost. The SUMO system provides facilities to increase protein yield and is a tool to rapidly purify the antigen. LifeSensors can guide scientists about the most suitable SUMO tag and the SUMO protease to efficiently remove SUMO to reduce cost of goods.
LifeSensors can guide you from your cloning strategy to selection of strains/cell lines for the best expression and establish a non-GMP process from gene to vaccine. The process can be easily adapted for downstream GMP production of vaccine.
- System Principle
Figure 2:Â The Principle of the system. SUMO Protease cleaves the SUMO 6xHis tag to separate the expressed vaccine to generate native vaccine. In many cases SUMO tag is not removed and SUMO-vaccine is as efficacious.
SUMO tag does not influence immunogenicity of the fused protein. The 6xHis is used to assist in purification while SUMO significantly improves expression.
- Applications & Research
LifeSensors pioneered the application of the SUMO system to enhance production of polypeptides as published by Marblestone et. Al, Protein Sci. 2006. SUMO system is superior to several other tags: 6xHis, Ubiquitin, MBP, GST, and TRX.
- Cost Effectiveness
Key Advantage
- Cost Effectiveness
Non-Immunogenic
SUMO is a highly conserved eukaryotic protein. In LifeSensors’ experience, SUMO tag is not immunogenic when injected into rabbits.
It is quite feasible to inject SUMO fusion vaccine as an immunogen, especially for veterinary applications, simplifying manufacturing and reducing costs.
- Resources
SUMO Vaccine Presentation
Comprehensive overview of SUMO technology in vaccine development
- SUMO Products
- SUMO Publication Sheet
To use, simply utilize the drop-down arrows in order to search for your target of interest or application category. LifeSensors SUMO technology has been utilized for the expression of many different targets and continues to be utilized worldwide.
- References
- 1.Prejit et al, Biologicals. 2019
- 2.Guo HC et al, Vet Res. 2013
- 3.Kim WS et al, Vaccines (Basel). 2020
- 4.Xiao Y et al, BMC Biotechnol. 2016
- 5.Xiao Y et al, Front Vet Sci. 2021
- 6.Li H et al, Vaccines (Basel). 2021
- 7.Du L et al, Virology. 2009
- 8.Tarczewska A et al, Int J Biol Macromol. 2021
- 9.Liu X et al, BMC Vet Res. 2020
- 10.Mustopa AZ et al, J Genet Eng Biotechnol. 2022
- 11.Mu S et al, Vaccines (Basel). 2020
- 12.Cibulski S et al, Front Immunol. 2021
- 13.Murphy N et al, Sci Rep. 2020